New Nicotine Alliance welcomes smoking and health action report

Sep.02.2022
New Nicotine Alliance welcomes smoking and health action report
New Nicotine Alliance welcomes report on smoking and health actions, highlighting evidence on youth e-cigarette use and dispelling myths.

The New Nicotine Alliance has welcomed the new Smoking and Health Action Plan briefing, stating that it directly addresses the issue of youth vaping. The briefing was released last week and the New Nicotine Alliance referred to it as "a timely document, given the constant media attention on the topic in recent weeks.


The New Nicotine Alliance has announced that its briefing on smoking and health has been endorsed by several public health organizations. The briefing objectively reviews current regulations and the latest evidence from surveys on youth e-cigarette use.


The most important aspect is that it exposes many of the myths recently seen in the media, which have negatively distorted public perception of electronic cigarette products. The New Nicotine Alliance further added that "the UK is globally leading in recognizing the benefits of reduced-risk products like e-cigarettes in helping smokers quit, and we are pleased that ASH has responded to recent negative news with calm and balanced evidenced-based arguments.


A disposable e-cigarette contains less nicotine than a pack of 20 cigarettes. In comparison, a standard 2ml disposable e-cigarette in the UK contains 40mg of nicotine, whereas the average pack of 20 cigarettes contains 250mg of nicotine.


Most young people who try vaping are unlikely to become addicted to nicotine. Vapers are much less likely to develop dependence compared to smokers.


Electronic cigarettes have been on sale in the UK for 15 years, and have been the most popular smoking cessation aid since 2013. During this time, there has been no association between electronic cigarettes and the prevalent health issues in the UK.


In 2019, a severe respiratory illness outbreak (known as "EVALI") in the United States was determined to be caused by vaping marijuana laced with vitamin E acetate, not by nicotine inhalation.


The New Nicotine Alliance continued to state that "ASH emphasized how anti-vaping campaigns have distorted the truth in the minds of the public, contrasting this with the clear information provided in New Zealand versus the destructive approach taken in the US, which has led some young people to conclude that they'd rather smoke than switch to vaping. While it's regrettable that irresponsible media coverage should make such truth-telling necessary, we warmly welcome ASH's intervention and hope that local authorities and other organizations take note of this. In many other countries, moral panic about youth vaping has led to an erosion of controls over nicotine products, such that the benefits that smokers derive from switching to vaping have been entirely diminished or eradicated by restrictions and bans.


The New Nicotine Alliance continued to state, "We are pleased to see that the UK's public health organization has responded to clarify the facts with common sense and rationality, and to support the world's leading UK regulatory body in acknowledging that electronic cigarettes are an important means of helping smokers quit or significantly reducing their harm.


Statement


This article was compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The translation of this article is only for industry communication and research purposes.


Due to limitations in translation ability, this article may not fully reflect the original content. Please refer to the original text for accuracy.


2FIRSTS holds the same stance and position as the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related issues.


The compilation of information is owned by the original media source and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
FDA Grants PMTA Authorization to 11 ZYN ULTRA Nicotine Pouches, Bringing Total Authorized Pouches to 43
The U.S. Food and Drug Administration authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA through the premarket tobacco product application pathway on August 21, 2026. Ten of the authorized products have a labeled nicotine content of 9 mg, while ZYN ULTRA Smooth was authorized at 11 mg. The reviews were conducted through FDA’s nicotine pouch PMTA pilot program. FDA has now authorized 43 nicotine pouch products, including 23 through the pilot.
Aug.24
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Product | Philip Morris Korea Launches TEREA Limona Pearl, Expanding Fresh Blend Capsule Lineup to Five
Philip Morris Korea launched TEREA Limona Pearl in South Korea on August 31, 2026, expanding the TEREA Fresh Blend capsule tobacco stick lineup from four variants to five. Designed for the IQOS ILUMA series, the new stick combines a capsule with what the company calls a Fresh Filter. Philip Morris Korea describes the product as offering an aromatic, refreshing flavor profile with a cooling sensation, with an additional fresh note released when the capsule is crushed. The recommended retail price is KRW 4,800 per pack, with sales through IQOS stores and convenience stores nationwide. No reliable evidence has been found that the same Limona Pearl SKU was previously officially launched in another major IQOS market.
Sep.01
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09